Beyond randomised controlled trials: using prescription claims data to investigate ‘real-world’ safety of newly marketed medicines
Evidence regarding the efficacy and safety of medicines is mainly derived from randomised controlled trials (RCTs). However, in real life medicines are often prescribed to patients who would have been excluded from participating in RCTs due to factors such as age, multimorbidity, or concomitant medicine treatment. This project will investigate the ‘real world’ use and safety of newly marketed medicines. Data will be sourced from national and international prescription claims databases. This will include data from the Australian Pharmaceutical Benefits Scheme (PBS). This project will apply novel pharmacoepidemiological research methods.
Enhanced research experiences
This project will involve interdisciplinary collaboration between Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences and School of Public Health and Preventive Medicine, Monash University. Professor Danny Liew at the School of Public Health and Preventive Medicine is an international research leader in pharmacoepidemiology, clinical trials, health services research and health economics.
This international project will involve close collaboration between the Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University and the Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (UNC). It is anticipated that the PhD candidate will spend between 2 to 6 months of their candidature at UNC working with Assistant Professor Gang Fang. UNC Chapel Hill is the highest ranked pharmacy school in the United States. Professor Fang is a national and internationally renowned expert in pharmacoepidemiology and therapeutic strategies in the treatment and prevention of cardiovascular disease.